Role of tofacitinib in chronic plaque psoriasis

Comparative therapeutic evaluation of oral tofacitinib versus methotrexate in moderate to severe chronic plaque Psoriasis - A hospital based randomized control trial - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/069964

Enrollment

112

Registered

2024-07-04

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Tablet tofacitinib: Tablet tofacitinib 5 mg will be given orally twice daily for 16 weeks Control Intervention1: Tablet methotrexate: Tablet methotrexate will be given once weekly in th

Eligibility

Inclusion criteria

Inclusion criteria: 1.patients of 18 to 65 years of age 2.BSA more than 5% and PASI more than 3 3.Patients with well controlled diabetes, hypertension and thyroid disorder

Exclusion criteria

Exclusion criteria: 1. Patients not consenting to the study. 2. Patient with deranged biochemical profile. 3. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
Clinical response as indicated by PASI75 score after 16 weeks of treatmentTimepoint: 16 weeks	—

Secondary

Measure	Time frame
1. Assessing The Dermatology Life Quality Index (DLQI) before , during and after the completion of 16 months. 2. Assessing the changes in Severity of Nail Psoriasis Score (SNAPS) after completion of 16 weeks. 3. Clinical response indicated by change in BSA Timepoint: 16 weeks	—

Countries

India

Contacts

Public ContactDr Rohit Kumar Singh

Dept. of dermatology and venerology , All india institute of medical sciences , gorakhpur

dr.sunil_30@yahoo.co.in9838844937

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026